Aktuellt
SENASTE
Redeye provides its initial take on Surgical Science’s Q3 2022 report, which came in above our estimates. We judge that positives from the report include strong Educational Products sales (c14% above our estimates) and solid EBITDA and EBIT margins (both c4ppt higher than we estimated). Notable negatives include weak cash flow and a sequential decrease of c11% in simulation software license revenues in Q3, subject to significant quarterly fluctuations.
LÄS MER
